Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

5.320 -0.360 (-6.34%)

Streaming Delayed Price Updated: 11:24 AM EDT, Sep 9, 2026 Add to My Watchlist

Price and Volume

Volume	152,625
Open	5.640
Bid (Size)	5.310 (800)
Ask (Size)	5.330 (300)
Prev. Close	5.680
Today's Range	5.280 - 5.660
52wk Range	2.780 - 6.450
Shares Outstanding	83,399,377
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

September 08, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea (AVIR) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

HCV regimen met non-inferiority with 8-week dosing for non-cirrhotic patients.

Via The Motley Fool

Performance

YTD	+52.9%	+52.9%
1 Month	+6.0%	+6.0%
3 Month	+22.0%	+22.0%
6 Month	-12.1%	-12.1%
1 Year	+63.7%	+63.7%

More News

Atea Pharmaceuticals Q2 Earnings Call Highlights ↗

August 12, 2026

Via MarketBeat

Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom ↗

May 12, 2026

Via Chartmill

Atea Pharmaceuticals (NASDAQ:AVIR) Reports Q4 2025 Results as HCV and HEV Pipeline Advance ↗

March 05, 2026

Via Chartmill

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

August 05, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

July 28, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

July 14, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

June 25, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

May 27, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

May 13, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Q1 Earnings Call Highlights ↗

May 12, 2026

Via MarketBeat

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

May 05, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharma (AVIR) Earnings Call Transcript ↗

March 05, 2026

Via The Motley Fool

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 05, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

February 26, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

February 24, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround ↗

February 03, 2026

Via The Motley Fool

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. ↗

February 03, 2026

Via The Motley Fool

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

January 08, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 01, 2026

Via Chartmill

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

December 22, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Atea Pharmaceuticals, Inc. - common stock publicly traded?

Yes, Atea Pharmaceuticals, Inc. - common stock is publicly traded.

What exchange does Atea Pharmaceuticals, Inc. - common stock trade on?

Atea Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Atea Pharmaceuticals, Inc. - common stock?

The ticker symbol for Atea Pharmaceuticals, Inc. - common stock is AVIR on the Nasdaq Stock Market

What is the current price of Atea Pharmaceuticals, Inc. - common stock?

The current price of Atea Pharmaceuticals, Inc. - common stock is 5.320

When was Atea Pharmaceuticals, Inc. - common stock last traded?

The last trade of Atea Pharmaceuticals, Inc. - common stock was at 09/09/26 11:24 AM ET

What is the market capitalization of Atea Pharmaceuticals, Inc. - common stock?

The market capitalization of Atea Pharmaceuticals, Inc. - common stock is 443.68M

How many shares of Atea Pharmaceuticals, Inc. - common stock are outstanding?

Atea Pharmaceuticals, Inc. - common stock has 444M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.